The Janssen Pharmaceutical Companies of Johnson & Johnson has announced results from the Phase 1b/2 NORSE (NCT03473743) study evaluating erdafitinib in combination with cetrelimab, an anti-programmed cell death protein 1 (PD-1) monoclonal antibody, compared to erdafitinib monotherapy in patients with locally advanced or metastatic urothelial carcinoma (mUC) with fibroblast growth factor receptor (FGFR)3 or FGFR2 genetic alterations who are ineligible for cisplatin, a current standard of care treatment for mUC. The results were highlighted in an oral presentation at the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting on earlier this month (Abstract #LBA27). Preliminary findings …
Read the source article at Pharma Business International
2021-09-28 08:04:16
